Assessment of geographic access to monoclonal antibodies in the United States-Reference-Cited by-同舟云学术

Assessment of geographic access to monoclonal antibodies in the United States

Published:2022-03-04 Issue: Volume: Page:
ISSN:1195-1982
Container-title:Journal of Travel Medicine
language:en
Short-container-title:

Author:

Rader Benjamin¹²^ORCID,Whaley Christopher M³,Rogers Wesley S⁴,Brownstein Professor John S¹⁵,Cantor Jonathan³

Affiliation:

1. Computational Epidemiology Lab, Boston Children’s Hospital, Boston, MA, USA

2. Department of Epidemiology, Boston University School of Public Health, Boston, MA, USA

3. RAND Corporation, Santa Monica, CA, USA

4. NewYork- Presbyterian Hospital - Weill Cornell Medical Center, New York, NY, USA

5. Harvard Medical School, Havard University, Boston, MA, USA

Abstract

Using spatial modeling techniques, we highlight disparities in access to monoclonal antibodies (mAbs) used to treat COVID-19 patients. Fifteen million individuals in the United States must travel over 30 min to access mAbs. Areas with lower COVID-19 vaccination rates have worse access to essential COVID-19 therapeutics.

Funder

Tides Foundation

National Institute on Aging

Publisher

Oxford University Press (OUP)

Subject

General Medicine

Link

https://academic.oup.com/jtm/advance-article-pdf/doi/10.1093/jtm/taac018/43710865/taac018.pdf

Reference10 articles.

1. The challenges ahead with monoclonal antibodies: from authorization to access;Goldstein;JAMA,2020

2. Fair allocation of scarce therapies for COVID-19;Persad;Clin Infect Dis,2021